These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 23555212)
1. Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment. Zhang W; Ota T; Shridhar V; Chien J; Wu B; Kuang R PLoS Comput Biol; 2013; 9(3):e1002975. PubMed ID: 23555212 [TBL] [Abstract][Full Text] [Related]
2. AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer. Svoboda M; Meshcheryakova A; Heinze G; Jaritz M; Pils D; Castillo-Tong DC; Hager G; Thalhammer T; Jensen-Jarolim E; Birner P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Zimmermann P; Zeillinger R; Mechtcheriakova D BMC Genomics; 2016 Aug; 17(1):643. PubMed ID: 27527602 [TBL] [Abstract][Full Text] [Related]
3. Identification of pathway-based recurrence-associated signatures in optimally debulked patients with serous ovarian cancer. Deng K; Zhang F; Song W; Zhao W; Rong Z; Cai Y; Xu H; Lu M; Wang W; Li A; Hou Y; Li Z; Li K J Cell Biochem; 2018 Nov; 119(10):8564-8573. PubMed ID: 30126000 [TBL] [Abstract][Full Text] [Related]
4. Identifying prognostic signature in ovarian cancer using DirGenerank. Wang JY; Chen LL; Zhou XH Oncotarget; 2017 Jul; 8(28):46398-46413. PubMed ID: 28615526 [TBL] [Abstract][Full Text] [Related]
5. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs. Zhao Q; Fan C BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053 [TBL] [Abstract][Full Text] [Related]
6. Novel gene signatures for prognosis prediction in ovarian cancer. Bao M; Zhang L; Hu Y J Cell Mol Med; 2020 Sep; 24(17):9972-9984. PubMed ID: 32666642 [TBL] [Abstract][Full Text] [Related]
7. Investigating the utility of clinical outcome-guided mutual information network in network-based Cox regression. Jeong HH; Kim S; Wee K; Sohn KA BMC Syst Biol; 2015; 9 Suppl 1(Suppl 1):S8. PubMed ID: 25708115 [TBL] [Abstract][Full Text] [Related]
8. Establishment of a SVM classifier to predict recurrence of ovarian cancer. Zhou J; Li L; Wang L; Li X; Xing H; Cheng L Mol Med Rep; 2018 Oct; 18(4):3589-3598. PubMed ID: 30106117 [TBL] [Abstract][Full Text] [Related]
9. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis. Wu M; Sun Y; Wu J; Liu G Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586 [TBL] [Abstract][Full Text] [Related]
10. The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer. Matondo A; Jo YH; Shahid M; Choi TG; Nguyen MN; Nguyen NNY; Akter S; Kang I; Ha J; Maeng CH; Kim SY; Lee JS; Kim J; Kim SS Sci Rep; 2017 Aug; 7(1):9689. PubMed ID: 28851888 [TBL] [Abstract][Full Text] [Related]
11. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network. Sun M; Wu D; Zhou K; Li H; Gong X; Wei Q; Du M; Lei P; Zha J; Zhu H; Gu X; Huang D Breast Cancer Res Treat; 2019 May; 175(1):59-75. PubMed ID: 30715658 [TBL] [Abstract][Full Text] [Related]
12. Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence. Delfino KR; Rodriguez-Zas SL PLoS One; 2013; 8(3):e58608. PubMed ID: 23554906 [TBL] [Abstract][Full Text] [Related]
13. Identification of an energy metabolism‑related gene signature in ovarian cancer prognosis. Wang L; Li X Oncol Rep; 2020 Jun; 43(6):1755-1770. PubMed ID: 32186777 [TBL] [Abstract][Full Text] [Related]
14. KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer. Zhao H; Guo E; Hu T; Sun Q; Wu J; Lin X; Luo D; Sun C; Wang C; Zhou B; Li N; Xia M; Lu H; Meng L; Xu X; Hu J; Ma D; Chen G; Zhu T Oncotarget; 2016 Jul; 7(28):43924-43938. PubMed ID: 27270322 [TBL] [Abstract][Full Text] [Related]
15. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer. Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627 [TBL] [Abstract][Full Text] [Related]
16. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma. Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564 [TBL] [Abstract][Full Text] [Related]
17. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer. Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416 [TBL] [Abstract][Full Text] [Related]
18. Clinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study. Zhu L; Wang H; Jiang C; Li W; Zhai S; Cai X; Wang X; Liao L; Tao F; Jin D; Chen G; Xia Y; Mao JH; Li B; Wang P; Hang B EBioMedicine; 2020 Nov; 61():103023. PubMed ID: 33069062 [TBL] [Abstract][Full Text] [Related]
19. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. Yoshihara K; Tajima A; Yahata T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Kotera K; Masuzaki H; Tashiro H; Katabuchi H; Inoue I; Tanaka K PLoS One; 2010 Mar; 5(3):e9615. PubMed ID: 20300634 [TBL] [Abstract][Full Text] [Related]
20. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]